MedTrace Logo

Cytoflavin in Combination With Reperfusion in Stroke Patients

NCT05297851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-03-20

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment within the first 24 hours from the stroke onset, compared to treament with any other neuroprotective drug which may be used in routine clinical practice.

Conditions

  • Acute Stroke

Interventions

DRUG

Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)

10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.

DRUG

Control

Standard treatment accordind to the routine clinical practice

Sponsors & Collaborators

  • POLYSAN Scientific & Technological Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • Dina R Khasanova, prof. · Interregional Clinical and Diagnostic Center, Kazan, Russia

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-10
Primary Completion
2023-02-28
Completion
2023-03-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05297851 on ClinicalTrials.gov